Quarterly ResultJul 29, 2026, 04:12 PM
Dyne Therapeutics Q2 Net Loss $(178.6)M; R&D Up 53%
AI Summary
Dyne Therapeutics reported a net loss of $(178.6) million for the second quarter of 2026, an increase from $(110.9) million in the prior year, as research and development expenses rose significantly to $152.2 million. For the six months ended June 30, 2026, the net loss was $(299.4) million. The company secured additional funding through an amended loan agreement with Hercules, providing up to $400.0 million in term loans, and expects its current cash to fund operations for at least 12 months.
Key Highlights
- Net loss for Q2 2026 was $(178.6) million, compared to $(110.9) million in Q2 2025.
- Research and development expenses increased 53% to $152.2 million in Q2 2026.
- General and administrative expenses rose to $29.5 million in Q2 2026.
- Cash and cash equivalents stood at $676.1 million as of June 30, 2026.
- Long-term debt, net, increased to $199.3 million as of June 30, 2026.
- Net cash used in operating activities for H1 2026 was $(275.2) million.
- Loan Agreement with Hercules amended, providing up to $400.0 million in term loans.
Price Impact
More from DYN